Safety and Tolerability of Methylphenidate in Preschool Children With ADHD

Wigal, Tim; Greenhill, Laurence L.; Chuang, Shirley; McGough, James J.; Vitiello, Benedetto; Skrobala, Anne M.; Swanson, James M.; Wigal, Sharon B.; Abikoff, Howard; Kollins, Scott H.; McCracken, James T.; Riddle, Mark A.; Posner, Kelly; Ghuman, Jaswinder K.; Davies, Mark; Thorp, Ben; Stehli, Annamarie

doi:10.1097/01.chi.0000235082.63156.27

Cited by 204 publications

(162 citation statements)

References 17 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…Efficacy was more limited than in school-age children [12] and there were significant levels of side effects [19]. A substantial minority of parents were reluctant to place their children on medication [40]. These factors, combined with the more general concern amongst parents and clinicians about using stimulants with young children makes empirical testing of non-pharmacological treatments for ADHD preschoolers a public health priority.…”

Section: Introductionmentioning

confidence: 99%

A small-scale randomized controlled trial of the revised new forest parenting programme for preschoolers with attention deficit hyperactivity disorder

Thompson

Laver-Bradbury

Ayres³

et al. 2009

Eur Child Adolesc Psychiatry

Self Cite

134

View full text Add to dashboard Cite

The revised new forest parenting programme (NFPP) is an 8-week psychological intervention designed to treat ADHD in preschool children by targeting, amongst other things, both underlying impairments in self-regulation and the quality of mother–child interactions. Forty-one children were randomized to either the revised NFPP or treatment as usual conditions. Outcomes were ADHD and ODD symptoms measured using questionnaires and direct observation, mothers’ mental health and the quality of mother–child interactions. Effects of the revised NFPP on ADHD symptoms were large (effect size >1) and significant and effects persisted for 9 weeks post-intervention. Effects on ODD symptoms were less marked. There were no improvements in maternal mental health or parenting behavior during mother–child interaction although there was a drop in mothers’ negative and an increase in their positive comments during a 5-min speech sample. The small-scale trial, although limited in power and generalizability, provides support for the efficacy of the revised NFPP. The findings need to be replicated in a larger more diverse sample

show abstract

Section: Introductionmentioning

confidence: 99%

A small-scale randomized controlled trial of the revised new forest parenting programme for preschoolers with attention deficit hyperactivity disorder

Thompson

Laver-Bradbury

Ayres³

et al. 2009

Eur Child Adolesc Psychiatry

Self Cite

134

View full text Add to dashboard Cite

show abstract

“…Mostly characterized by symptoms like hyperactivity, inattention and impulsivity (1), attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders in childhood (2). Its worldwide prevalence in children is estimated to be 5.29% (1).…”

Section: Introductionmentioning

confidence: 99%

“…Although the effect of psycho-stimulants in children under 6 years are less compared to older age (2). Besides, they experience more side effects of stimulants and increasingly turn to switch to other medications like antipsychotics (2,3). Haloperidol and Largactil are the two first approved medications in USA for short-term control of ADHD in children (4).…”

Section: Introductionmentioning

confidence: 99%

A Comparative Study of Risperidone and Aripiprazole in Attention Deficit Hyperactivity Disorder in Children Under Six Years Old: A Randomized Double-Blind Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…59 MPH doses were tolerated by 92% of 183 patients in the treatment group during a 1-week open safety lead-in phase. 60 The 165 patients randomized to MPH in the 5-week, placebo-controlled, double-blind phase of the study had smaller effect sizes (0.4 to 0.8) than did school-age children in the MTA study. Side effects, such as appetite loss, trouble sleeping, stomach aches, social withdrawal, and lethargy, were reported more often with the high MPH doses across the study.…”

Section: Safety In Young Adhd Patientsmentioning

confidence: 99%

“…No cardiovascular side effects required follow-up. 60 Growth rates were lower than expected for height and weight in this segment of the study, 61 and investigators plan a 5-year follow-up study to examine the risk-benefit effects of treatment as children age.…”

Section: Safety In Young Adhd Patientsmentioning

confidence: 99%